Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.62 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.62 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3206162 | 0.80 | QPCT (0.68) | QPCTQPCTLCYP17A1HSD17B10LMNA | |
| SCHEMBL3224099 | 0.79 | IDO1 (0.49) | QPCTQPCTLCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3220223 | 0.77 | QPCT (0.65) | QPCTQPCTLCYP17A1LMNAKDM4E | |
| SCHEMBL3224883 | 0.76 | QPCT (0.51) | QPCTQPCTLCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL3227840 | 0.76 | QPCT (0.51) | QPCTQPCTLCYP17A1CYP1A2KDM4E | |
| SCHEMBL12698831 | 0.76 | QPCT (0.59) | QPCTQPCTLCYP17A1IDO1CYP11B1 | |
| SCHEMBL3260750 | 0.75 | QPCT (0.67) | QPCTQPCTLCYP17A1IDO1CYP11B1 | |
| SCHEMBL3227909 | 0.74 | QPCT (0.64) | QPCTQPCTLCYP17A1JAK2IDO1 | |
| SCHEMBL3218135 | 0.74 | QPCT (0.72) | QPCTQPCTLCYP1A2CYP3A4HSD17B10 | |
| SCHEMBL14833486 | 0.73 | CYP17A1 (0.69) | QPCTQPCTLCYP17A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118101-B1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-26 | — | — | EP | claimed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | claimed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | claimed |
| EP-2118101-B1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-26 | — | — | EP | disclosed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | disclosed |
| EP-2118101-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| WO-2008110523-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110523-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234313-A1 | NOVEL INHIBITORS | SF3A1, HBS1L, SF3A3 | QPCT 4475/4885QPCTL 4381/4885CYP17A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.